<DOC>
	<DOC>NCT02975700</DOC>
	<brief_summary>The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.</brief_summary>
	<brief_title>A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Age ≥ 18 years Unresectable stage III or stage IV melanoma which is histologically confirmed at the treating institution with KIT mutation(s) not known to be resistant to PLX3397 Presence of measurable lesions by Response Evaluation Criteria in Solid Tumors Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 02 Life expectancy ≥ 3 months Adequate organ and bone marrow function Women of childbearing potential must have a negative serum pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 3 months after the last dose of study drug. Women of nonchildbearing potential must have been postmenopausal for ≥ 1 year or surgically sterile. Fertile men must agree to use an effective method of birth control during the study and for up to 3 months after the last dose of study drug. Willingness and ability to provide written informed consent prior to any studyrelated procedures and to comply with all study requirements Prior treatment with a KIT inhibitor for melanoma Presence of NRAS or BRAF mutation Exposure to any investigational drug within 28 days or unresolved adverse effects from previous therapy Symptomatic brain metastases. Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Sponsor Concomitant treatment with other antineoplastic agents (hormonal therapy acceptable) Uncontrolled intercurrent or infectious illness Major surgical procedure or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the study Previous radiotherapy to 25% or more of the bone marrow and/or radiation therapy within 28 days prior to study entry Inability to swallow capsules, or refractory nausea and vomiting, malabsorption, an external biliary shunt, or significant bowel resection that would preclude adequate absorption Congestive heart failure (CHF) New York (NY) Heart Association class III or IV; unstable coronary artery disease (myocardial infarction [MI] more than 6 months prior to study entry is permitted); or serious cardiac arrhythmia Baseline QTcF ≥ 450 msec (for males) or ≥ 470 msec (for females) at Screening Active or chronic infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) Known chronic liver disease Women who are breastfeeding or pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PLX3397</keyword>
	<keyword>Kit-mutant Melanoma</keyword>
</DOC>